QNTM 6-K: SEC filing

Quantum BioPharma Ltd.

Filed with the SEC on · accession 0001171843-26-007369

QNTM filed a 6-K (foreign company report) with the SEC on Nov 12, 2026. Quantum BioPharma Ltd. filed a Form 6-K furnishing a press release dated November 11, 2026.

Summary of the filing

Quantum BioPharma Ltd. filed a Form 6-K furnishing a press release dated November 11, 2026. The filing itself contains no substantive details about the press release's contents beyond its attachment as Exhibit 99.1.

Key details

RegistrantQuantum BioPharma Ltd.
Chief financial officerDonal Carroll

✦ Ask GOAX AI about this filing — what it means for QNTM, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for QNTM?

Click here

Frequently asked questions

What did QNTM file with the SEC on Nov 12, 2026?

QNTM filed a 6-K (SEC filing). Quantum BioPharma Ltd. filed a Form 6-K furnishing a press release dated November 11, 2026. The filing itself contains no substantive details about the press release's contents beyond its attachment as Exhibit 99.1.

How do I read a 6-K?

How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.

Other QNTM SEC filings

Get alerts when QNTM files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days